Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis

BACKGROUND AND AIMS: The multi-kinase inhibitor sorafenib is a first-line drug for patients with advanced hepatocellular carcinoma (HCC). Treatment options for patients whose disease has progressed on sorafenib are limited. In a recent randomized controlled trial (CELESTIAL trial), patients with adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Shlomai, Amir, Leshno, Moshe, Goldstein, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759721/
https://www.ncbi.nlm.nih.gov/pubmed/31579104
http://dx.doi.org/10.1177/1756284819878304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759721/
https://www.ncbi.nlm.nih.gov/pubmed/31579104
http://dx.doi.org/10.1177/1756284819878304

Ejemplares similares